Who
Vikas Sinha
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Scholar Rock Holding; Director, Verona Pharma; Director and Officer and 10% owner, Kalaris Therapeutics; EVP & CFO, Alexion Pharmaceuticals.
In numbers
- Trades disclosed
- 306
- Buys
- 0
- Sells
- 120
- Bought
- $0
- Sold
- $84.9M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 9 Jan 2006
- Last trade
- 16 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $516K10,410 at $49.57 | filing |
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $516K10,410 at $49.57 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —47,021 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —47,021 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $715K16,755 at $42.70 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $715K16,755 at $42.70 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —72,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code D | —384 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code D | —96,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code D | —240,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code D | —64,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code D | —94,112 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code M | —72,000 | filing |
| 7 Oct 2025filed 8 Oct 2025 | Verona Pharma | SEC FORM 4 Code D | —72,000 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharma | SEC FORM 4 Code M | —24,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | Verona Pharma | SEC FORM 4 Sold | $57K4,328 at $13.14 | filing |
| 20 May 2025filed 22 May 2025 | Verona Pharmaoption or derivative | SEC FORM 4 Code M | —160,000 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | Verona Pharma | SEC FORM 4 Code M | $80K160,000 at $0.50 | filing |
| 20 May 2025filed 22 May 2025 | Verona Pharma | SEC FORM 4 Sold | $1.5M160,000 at $9.39 | filing |
News
Anuradha and Vikas Sinha Donate $20M to Launch UNT AI Collegeindiawest.com · 16 Oct 2026UNT receives transformative USD 20 mn gift from alumnus Vikas Sinha and family to launch AI collegebignewsnetwork.com · 10 Sep 2026NRIs Anuradha and Vikas Sinha Couple Donates $20 Million to Launch AI and Advanced Analytics Collegenripress.com · 10 Sep 2026Anuradha Vikas Sinha, Indian-origin couple donation, $20 million UNT donation, University of North Texas AI, UNT artificial intelligence, advanced analytics, Sinha College of AI, AI education Texas, data science, AI research, Indian Americans, Vikas Sinha Broadcom, Harrison Keller, Sinha Innovation Labdailypioneer.com · 10 Sep 2026University Of North Texas Names New AI College After Indian-Origin Couple Anuradha And Vikas Sinha Following ₹190 Crore Donationfreepressjournal.in · 10 Sep 2026Anuradha And Vikas Sinha Establish AI College At UNT With $20 Million Giftrediff.com · 9 Sep 2026Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026
6 headlines in the last 90 days name Vikas Sinha; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.